Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomics effects of IFNb and IFNg stimulation on murine cancer cell lines

ABSTRACT: Transcriptomics effects of IFNb and IFNg stimulation on murine cancer cell lines

PROVIDER: PRJNA850930 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomics effects of IFNb and IFNg stimulation on murine cancer cell lines

Project description:To measure the transcriptomic changes in response to IFNb and IFNg stimulation, we collected RNAseq of various cell lines that were stimulated or unstimulated by interferon for 48 hours

2022-08-01 | GSE206443 | GEO

Stimulation of Caco-2 cells with IFNg

Project description:Stimulation of Caco-2 cells with IFNg

| PRJNA612310 | ENA

Single-cell RNA-seq of dermal fibroblasts (5 human individuals - IFNB stimulation)

Project description:Single-cell RNA-seq of dermal fibroblasts (5 human individuals - IFNB stimulation)

| PRJEB27795 | ENA

Effects of FTY720/IFNb on astrocytes

Project description:Combinatorial FTY720/IFNb induces protective factors in astrocytes

| PRJEB48316 | ENA

Single-cell RNA-seq of dermal fibroblasts (5 human individuals - IFNB stimulation)

Project description:Single-cell RNA-seq of human dermal fibroblasts, stimulated with IFNB 1000 IU for 2 or 6 hours, and profiled using the SmartSeq2 protocol.

2018-07-16 | E-MTAB-7051 | biostudies-arrayexpress

Response of several cell lines originated from liver, skin and colon to stimulation by IFNg, hyper-IL6, IL27 and OSM, investigated at mRNA level

Project description:In this study 6 cell lines originated from liver, skin and colon tumours as well as 3 non-tumour cell lines from the same organs were profiled with and without stimulation by 4 cytokines: IFNg, hyper-IL6, IL27 and OSM. The main objective was investigation of downstream effects of the stimulation if these cancer cell lines as well as in healthy tissues.

2018-10-01 | E-MTAB-6080 | biostudies-arrayexpress

Response of several cell lines originated from liver, skin and colon to stimulation by IFNg, hyper-IL6, IL27 and OSM, investigated at microRNA level

2021-04-07 | E-MTAB-9118 | biostudies-arrayexpress

Differential gene expression in IFNg+ and IFNg- IL-15 primed NK cells after anti-NK1.1 stimulation [IFNgReporter_RNA-seq]

Project description:Differential gene expression in IFNg+ and IFNg- IL-15 primed NK cells after anti-NK1.1 stimulation [IFNgReporter_RNA-seq]

| PRJNA947202 | ENA

Transcriptome profiling of primary murine fibroblast response to IFNB with or without prior Drosha depletion

Project description:To assess the impact of Drosha on the response to IFNB

2017-06-28 | GSE96889 | GEO

Pharmacogenomics of IFNb therapy

Project description:This experiment set is used for the manuscript entitled: Pharmacogenomics of Interferon-b therapy in multiple sclerosis: Baseline IFN signature determines pharmacological differences between patients. In this study we generated and analyzed pre- and post- IFNb treatment gene expression patterns of RRMS patients with the aim of identifying pre-existing and/or drug-induced signatures that will allow us to make predictions on the expected pharmacological effects of IFNb treatment. We show that the expression level of IFN response genes prior to treatment, determines the pharmacological differences between patients with MS at the molecular level. A group of 16 Dutch patients (10 females and 6 males) with clinically definite relapsing-remitting MS was recruited from the outpatient clinic of the MS Centre Amsterdam. Mean age at start of IFNb therapy is 40.6 +/- 7.7, mean EDSS is 2.3 +/- 1.3 (range 1-6). Blood samples were obtained just before treatment and 1 month after start of the therapy. Patients received Avonex, Betaferon, Rebif 22 or Rebif 44. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Before and 1 month after IFNb therapy Keywords: compound_treatment_design Complex

2008-04-01 | E-GEOD-10655 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data